In Cell this week: variants linked to enhanced branching among tomatoes, innate and adaptive immune response to Zostavax vaccination, and more.
The researchers used mass cytometry to characterize dozens of markers in 3.5 million immune cells in samples from 73 clear cell renal cell carcinoma patients.
The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.
In Genome Biology this week: methylation changes in aging, single-cell RNA sequencing of renal cell carcinoma tumor, and more.
A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.
Members of TCGA characterized papillary renal cell carcinomas, uncovering two main tumor groups and several more prognostically informative subtypes.
Roche is investigating the drug candidate for non small cell lung cancer, triple-negative breast cancer, and renal cell carcinoma.
Rosetta Genomics has published a study describing the development and initial validation of its miRview Kidney test, a 24-microRNA array-based assay that classifies a patient's primary kidney tumor into one of four main subtypes.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.